CV Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the total of the same amounts shown in the statement of cash flows as of December 31, 2020 and 2019 (in thousands):


	As of December 31,
	2020		2019
Cash and cash equivalents	$	4,024	$	9,107
Restricted cash	501		501
Total cash and restricted cash shown in the statements of cash flows	$	4,525	$	9,608

Revenue Product Sales by Channel

The following represents product sales by channel for food, drug and mass ("FDM"), natural product and other, and e-commerce for the years ended December 31, 2020 and 2019:


	For the years ended December 31,
	2020				2019
	(in thousands)				(in thousands)
	Amount		% of product sales, net		Amount		% of prodct sales, net
Retail - FDM	$	1,651	6.8	%	$	2,229	4.2	%
Retail - Natural products and other	15,073		61.7	%	41,534		77.3	%
E-Comm	7,705		31.5	%	9,933		18.5	%
Product sales, net	$	24,429	100.0	%	$	53,696	100.0	%